NCI Trials for September

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

For further information, contact the principal investigator listed.


Phase I – ABTC-1701

Pilot Surgical PK Study of BGB324 in Recurrent Glioblastoma Patients

Adult Brain Tumor Consortium

Nakano, Ichiro

(205) 934-1813


Phase I/II – 10096

A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer with Bone Metastases (COMRADE)

Yale University Cancer Center LAO

McKay, Rana Ramzi

(858) 822-6185


Phase II – 10144

A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma with DNA-Repair Defects

National Cancer Institute LAO

Apolo, Andrea Borghese

(301) 480-0536


Phase II – AMC-102

A Randomized Phase II Trial of Concurrent Chemotherapy and Pelvic Radiation Therapy with or Without Paclitaxel and Carboplatin in HIV-Positive Women with Locally Advanced Cervical Cancer (LACC)

AIDS Malignancy Consortium

Ndlovu, Ntokozo

2634791631 X 2264


Phase II – NRG-GY012

A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer

NRG Oncology

Mackay, Helen Jane

(416) 946-2000


Phase III – S1614

A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors

SWOG

Hwang, Jessica P.

(713) 745-4516


Phase III – S1802

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

SWOG

Chapin, Brian Francis

(713) 794-5590


Phase Other – AALL18B3-Q

Discovery of the Genetic Basis of ALL in Children with Down Syndrome

Children’s Oncology Group

Rabin, Karen Ruth

(832) 824-4213


Phase Other – AMC-A04

Development of a Health-Related Symptom Index for Spanish-Speaking Persons Diagnosed with and Either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions (HSIL)

AIDS Malignancy Consortium

Atkinson, Thomas Michael

(646) 888-0089


Phase Other – ECOG-ACRIN-EAQ161CD

Biomarker Testing in Common Solid Cancers: An Assessment of Current Practices in Precision Oncology in the Community Setting

ECOG-ACRIN Cancer Research Group

Trosman, Julia

(224) 619-2900


Phase Other – WF-1801

A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy

Wake Forest NCORP Research Base

Chan, Michael D.

(336) 713-3600

Table of Contents

YOU MAY BE INTERESTED IN

“I don’t know of a single grant that left my desk that was not approved and funded,” NCI Director Anthony G. Letai said on this episode of The Cancer Letter Podcast. https://open.spotify.com/episode/2PFYGwliBDYEbxBXFd9MtB?si=95DNBAy0QGSKBX31_uETEA This episode is available on Spotify, Apple Podcasts, and Youtube. Letai recapped his first year as NCI director in conversation with Paul Goldberg,...

A year ago, when he was sworn in as director of the National Cancer Institute, Anthony G. Letai set a goal: Reassure cancer researchers that the institute will keep a steady course aimed at finding treatments for cancer.
Michael R. Caputo, a cancer survivor and a Republican political operative with a wide-ranging resume, was named to the President’s Cancer Panel, a board formed under the National Cancer Act to monitor the National Cancer Program and report to the president about “barriers to progress in reducing the burden of cancer.”
For over two decades, the ASCO Genitourinary Cancers Symposiumhas stood as the premier global event that has helped advance cancer science and transform care. The 2027 Symposium will continue this legacy from Feb. 11–13 in San Francisco by bringing together the largest international audience in GU oncology to help define tomorrow’s standards of care. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login